Antiphospholipid Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major antiphospholipid syndrome markets reached a value of US$ 29.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 74.5 Million by 2034, exhibiting a growth rate (CAGR) of 8.79% during 2024-2034.
The antiphospholipid syndrome market has been comprehensively analyzed in IMARC's new report titled "Antiphospholipid Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Antiphospholipid syndrome refers to an autoimmune condition characterized by the development of antiphospholipid antibodies in the blood, which might increase the risk of blood clot formation. These antibodies mistakenly target the body's cell membranes and proteins, specifically phospholipids, triggering an inflammatory response and causing abnormal clotting in blood vessels. The symptoms of the illness can vary and may include recurring blood clots in veins and arteries, leading to deep vein thrombosis (DVT), pulmonary embolism, and strokes. Additionally, individuals suffering from the ailment might experience recurrent miscarriages or complications during pregnancy. The diagnosis of antiphospholipid syndrome involves a combination of symptom evaluation, medical history assessment, and laboratory tests to detect the presence of biomarkers. The criteria for diagnosis include the occurrence of clinical events associated with the disease and persistently positive test results for some specific antibodies. Early prognosis and management are crucial in this disorder to prevent potentially life-threatening complications and improve patient outcomes.
The increasing cases of autoimmune disorders that can affect phospholipid-binding proteins, leading to abnormal blood clotting, recurrent thrombosis, and pregnancy complications, are primarily driving the antiphospholipid syndrome market. In addition to this, the inflating utilization of effective medications, including anticoagulants, antiplatelets, corticosteroids, etc., to manage and control clotting episodes is also creating a positive outlook for the market. These therapeutic interventions play a crucial role in preventing further damage and improving patient outcomes. Moreover, the widespread adoption of physical and occupational therapies to enhance joint flexibility, reduce pain, and boost overall quality of life for individuals suffering from antiphospholipid syndrome is bolstering the market growth. Apart from this, the rising application of gene therapy, since it offers the potential to correct the genetic abnormalities associated with the condition, thereby providing a groundbreaking approach towards effective disease management and long-term remission, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of innovative treatment approaches, such as targeted biologics and immune-modulating therapies, which work to restore the balance of the immune system, minimize the production of harmful antibodies, and mitigate the risk of clot formation, is expected to drive the antiphospholipid syndrome market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the antiphospholipid syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for antiphospholipid syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the antiphospholipid syndrome market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the antiphospholipid syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the antiphospholipid syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current antiphospholipid syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the antiphospholipid syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the antiphospholipid syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the antiphospholipid syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of antiphospholipid syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of antiphospholipid syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of antiphospholipid syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with antiphospholipid syndrome across the seven major markets?
What is the size of the antiphospholipid syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of antiphospholipid syndrome?
What will be the growth rate of patients across the seven major markets?
Antiphospholipid Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for antiphospholipid syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the antiphospholipid syndrome market?
What are the key regulatory events related to the antiphospholipid syndrome market?
What is the structure of clinical trial landscape by status related to the antiphospholipid syndrome market?
What is the structure of clinical trial landscape by phase related to the antiphospholipid syndrome market?
What is the structure of clinical trial landscape by route of administration related to the antiphospholipid syndrome market?
The antiphospholipid syndrome market has been comprehensively analyzed in IMARC's new report titled "Antiphospholipid Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Antiphospholipid syndrome refers to an autoimmune condition characterized by the development of antiphospholipid antibodies in the blood, which might increase the risk of blood clot formation. These antibodies mistakenly target the body's cell membranes and proteins, specifically phospholipids, triggering an inflammatory response and causing abnormal clotting in blood vessels. The symptoms of the illness can vary and may include recurring blood clots in veins and arteries, leading to deep vein thrombosis (DVT), pulmonary embolism, and strokes. Additionally, individuals suffering from the ailment might experience recurrent miscarriages or complications during pregnancy. The diagnosis of antiphospholipid syndrome involves a combination of symptom evaluation, medical history assessment, and laboratory tests to detect the presence of biomarkers. The criteria for diagnosis include the occurrence of clinical events associated with the disease and persistently positive test results for some specific antibodies. Early prognosis and management are crucial in this disorder to prevent potentially life-threatening complications and improve patient outcomes.
The increasing cases of autoimmune disorders that can affect phospholipid-binding proteins, leading to abnormal blood clotting, recurrent thrombosis, and pregnancy complications, are primarily driving the antiphospholipid syndrome market. In addition to this, the inflating utilization of effective medications, including anticoagulants, antiplatelets, corticosteroids, etc., to manage and control clotting episodes is also creating a positive outlook for the market. These therapeutic interventions play a crucial role in preventing further damage and improving patient outcomes. Moreover, the widespread adoption of physical and occupational therapies to enhance joint flexibility, reduce pain, and boost overall quality of life for individuals suffering from antiphospholipid syndrome is bolstering the market growth. Apart from this, the rising application of gene therapy, since it offers the potential to correct the genetic abnormalities associated with the condition, thereby providing a groundbreaking approach towards effective disease management and long-term remission, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of innovative treatment approaches, such as targeted biologics and immune-modulating therapies, which work to restore the balance of the immune system, minimize the production of harmful antibodies, and mitigate the risk of clot formation, is expected to drive the antiphospholipid syndrome market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the antiphospholipid syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for antiphospholipid syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the antiphospholipid syndrome market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the antiphospholipid syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the antiphospholipid syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current antiphospholipid syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the antiphospholipid syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the antiphospholipid syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the antiphospholipid syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of antiphospholipid syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of antiphospholipid syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of antiphospholipid syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with antiphospholipid syndrome across the seven major markets?
What is the size of the antiphospholipid syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of antiphospholipid syndrome?
What will be the growth rate of patients across the seven major markets?
Antiphospholipid Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for antiphospholipid syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the antiphospholipid syndrome market?
What are the key regulatory events related to the antiphospholipid syndrome market?
What is the structure of clinical trial landscape by status related to the antiphospholipid syndrome market?
What is the structure of clinical trial landscape by phase related to the antiphospholipid syndrome market?
What is the structure of clinical trial landscape by route of administration related to the antiphospholipid syndrome market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ANTIPHOSPHOLIPID SYNDROME - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ANTIPHOSPHOLIPID SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ANTIPHOSPHOLIPID SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ANTIPHOSPHOLIPID SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ANTIPHOSPHOLIPID SYNDROME - UNMET NEEDS
10 ANTIPHOSPHOLIPID SYNDROME - KEY ENDPOINTS OF TREATMENT
11 ANTIPHOSPHOLIPID SYNDROME - MARKETED PRODUCTS
11.1 List of Antiphospholipid Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 ANTIPHOSPHOLIPID SYNDROME - PIPELINE DRUGS
12.1 List of Antiphospholipid Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13 ANTIPHOSPHOLIPID SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 ANTIPHOSPHOLIPID SYNDROME – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ANTIPHOSPHOLIPID SYNDROME - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Antiphospholipid Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Antiphospholipid Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Antiphospholipid Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Antiphospholipid Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Antiphospholipid Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Antiphospholipid Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Antiphospholipid Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Antiphospholipid Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Antiphospholipid Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Antiphospholipid Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Antiphospholipid Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Antiphospholipid Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Antiphospholipid Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Antiphospholipid Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Antiphospholipid Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Antiphospholipid Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Antiphospholipid Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Antiphospholipid Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Antiphospholipid Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Antiphospholipid Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Antiphospholipid Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Antiphospholipid Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Antiphospholipid Syndrome - Access and Reimbursement Overview
16 ANTIPHOSPHOLIPID SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ANTIPHOSPHOLIPID SYNDROME MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ANTIPHOSPHOLIPID SYNDROME MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ANTIPHOSPHOLIPID SYNDROME - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ANTIPHOSPHOLIPID SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ANTIPHOSPHOLIPID SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ANTIPHOSPHOLIPID SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ANTIPHOSPHOLIPID SYNDROME - UNMET NEEDS
10 ANTIPHOSPHOLIPID SYNDROME - KEY ENDPOINTS OF TREATMENT
11 ANTIPHOSPHOLIPID SYNDROME - MARKETED PRODUCTS
11.1 List of Antiphospholipid Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 ANTIPHOSPHOLIPID SYNDROME - PIPELINE DRUGS
12.1 List of Antiphospholipid Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13 ANTIPHOSPHOLIPID SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 ANTIPHOSPHOLIPID SYNDROME – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ANTIPHOSPHOLIPID SYNDROME - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Antiphospholipid Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Antiphospholipid Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Antiphospholipid Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Antiphospholipid Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Antiphospholipid Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Antiphospholipid Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Antiphospholipid Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Antiphospholipid Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Antiphospholipid Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Antiphospholipid Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Antiphospholipid Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Antiphospholipid Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Antiphospholipid Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Antiphospholipid Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Antiphospholipid Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Antiphospholipid Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Antiphospholipid Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Antiphospholipid Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Antiphospholipid Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Antiphospholipid Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Antiphospholipid Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Antiphospholipid Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Antiphospholipid Syndrome - Access and Reimbursement Overview
16 ANTIPHOSPHOLIPID SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ANTIPHOSPHOLIPID SYNDROME MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ANTIPHOSPHOLIPID SYNDROME MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
